BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 24431264)

  • 1. Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care.
    Clausen FB
    Prenat Diagn; 2014 May; 34(5):409-15. PubMed ID: 24431264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive fetal RhD genotyping from maternal blood.
    Kolialexi A; Tounta G; Mavrou A
    Expert Rev Mol Diagn; 2010 Apr; 10(3):285-96. PubMed ID: 20370586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects.
    Daniels G; Finning K; Martin P; Massey E
    Prenat Diagn; 2009 Feb; 29(2):101-7. PubMed ID: 19085963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive fetal RhD genotyping.
    Clausen FB; Damkjær MB; Dziegiel MH
    Transfus Apher Sci; 2014 Apr; 50(2):154-62. PubMed ID: 24642067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of maternal plasma for prenatal RhD blood group genotyping.
    Finning K; Martin P; Daniels G
    Methods Mol Biol; 2009; 496():143-57. PubMed ID: 18839110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.
    Müller SP; Bartels I; Stein W; Emons G; Gutensohn K; Köhler M; Legler TJ
    Transfusion; 2008 Nov; 48(11):2292-301. PubMed ID: 18694461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in fetal nucleic acids in maternal plasma: implications to noninvasive prenatal fetal blood group genotyping.
    Lo YM
    Transfus Clin Biol; 2006; 13(1-2):50-2. PubMed ID: 16563836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antenatal
    Clausen FB
    Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed.
    van der Schoot CE; Tax GH; Rijnders RJ; de Haas M; Christiaens GC
    Transfus Med Rev; 2003 Jan; 17(1):31-44. PubMed ID: 12522770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fetal blood group genotyping: present and future.
    Daniels G; Finning K; Martin P; Summers J
    Ann N Y Acad Sci; 2006 Sep; 1075():88-95. PubMed ID: 17108196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RHD genotyping from maternal plasma: guidelines and technical challenges.
    Avent ND
    Methods Mol Biol; 2008; 444():185-201. PubMed ID: 18425481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis.
    Clausen FB; Rieneck K; Krog GR; Bundgaard BS; Dziegiel MH
    Methods Mol Biol; 2019; 1885():347-359. PubMed ID: 30506209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new biosensor for noninvasive determination of fetal RHD status in maternal blood of RhD negative pregnant women.
    Dündar Yenilmez E; Kökbaş U; Kartlaşmış K; Kayrın L; Tuli A
    PLoS One; 2018; 13(6):e0197855. PubMed ID: 29874251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark.
    Clausen FB; Steffensen R; Christiansen M; Rudby M; Jakobsen MA; Jakobsen TR; Krog GR; Madsen RD; Nielsen KR; Rieneck K; Sprogøe U; Homburg KM; Baech J; Dziegiel MH; Grunnet N
    Prenat Diagn; 2014 Oct; 34(10):1000-5. PubMed ID: 24860987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis.
    Clausen FB; Christiansen M; Steffensen R; Jørgensen S; Nielsen C; Jakobsen MA; Madsen RD; Jensen K; Krog GR; Rieneck K; Sprogøe U; Homburg KM; Grunnet N; Dziegiel MH
    Transfusion; 2012 Apr; 52(4):752-8. PubMed ID: 21995641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemolytic disease of the fetus and newborn in the molecular era.
    Fasano RM
    Semin Fetal Neonatal Med; 2016 Feb; 21(1):28-34. PubMed ID: 26589360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin.
    Daniels G; Finning K; Martin P; Summers J
    Transfus Clin Biol; 2007 Dec; 14(6):568-71. PubMed ID: 18436463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
    Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT
    Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn.
    Daniels G; Finning K; Martin P; Soothill P
    Vox Sang; 2004 Nov; 87(4):225-32. PubMed ID: 15585017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive fetal RHD and RHCE genotyping using real-time PCR testing of maternal plasma in RhD-negative pregnancies.
    Hromadnikova I; Vechetova L; Vesela K; Benesova B; Doucha J; Vlk R
    J Histochem Cytochem; 2005 Mar; 53(3):301-5. PubMed ID: 15750007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.